Tadocizumab (C4G1) 是一种人源化靶向整合素 αIIbβ3 的单克隆抗体，具有抗血小板和抗血栓作用，阻断血小板 αIIbβ3 整合素 interac-与 brinogen 和 bronectin 作用，可用于研究心血管疾病。

Arginine-glycine-aspartic acid (RGD) 是一种细胞粘附基序，可以模拟细胞粘附蛋白并与整合素结合。

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro为FITC标记的GRGDSP，后者为整联蛋白(integrin)抑制剂，能阻止肿瘤细胞与血管内皮细胞粘附，进而抑制肿瘤转移。

Certepetide (CEND-1)，即双功能环肽（a.k.a. iRGD），是一种具有穿透肿瘤功能的多肽。通过与α-V整联蛋白（alphav-integrins）的RGD motif相互作用，以及激活神经纤毛蛋白1（NRP-1），Certepetide能够将实体瘤微环境转化成临时的活性分子通道，从而在肿瘤中累积。该化合物在胰腺癌和其他实体瘤的研究中具有应用潜力。

Sageone represents a promising anticancer agent against gastric cancer that warrants further study, it synergizes with cisplatin cytotoxicity in SNU-1 human gastric cancer cells.Sageone also shows antiviral activity.

Insulinglargine 是一种长效胰岛素类似物。Insulinglargine 可用于研究糖尿病。

α2β1 integrin inhibitor

CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by IL-2 expression[1]. CC-90005 shows the exquisite selectivity of CC-90005, with IC50s for all other family members of >3 μM[1].CC-90005 is a moderate inhibitor of both CYP2C9 (IC50=8 μM) and CYP2C19 (IC50=5.9 μM) in human liver microsomes[1].CC-90005 inhibits IL-2 expression in LRS_WBC human PBMCs, with an IC50 of 0.15 μM[1].CC-90005 (1-10 μM; 24 h) inhibits T cell proliferation in PBMCs by 51% at 1 μM and 88% at 3 μM[1]. CC-90005 (3-30 mg/kg; p.o. twice daily for 4 days) significantly reduces the popliteal lymph node (PLN) size in a model of chronic T cell activation[1].CC-90005 (100 mg/kg; a single p.o.) significantly inhibits plasma and spleen IL-2 release by 51 and 54%, respectively[1].CC-90005 exhibits reasonable oral bioavailability (66 and 46%) and Cmax (1.18 and 1

Fibronectin Type III Connecting Segment Fragment 1-25，一种多肽，主要作用于黑色素瘤细胞的粘附，并在鸡的周围神经系统发育中扮演关键角色。